Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: A nationwide danish population-based cohort study

European Urology

Volumn 65, Issue 4, 2014, Pages 704-709

  Jespersen, Christina G ^a   Nørgaard, Mette ^a   Borre, Michael ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Castration; Gonadotropin releasing hormone; Myocardial infarction; Orchiectomy; Prostatic neoplasms; Stroke

Indexed keywords

CASTRATION; GONADOTROPIN-RELEASING HORMONE; MYOCARDIAL INFARCTION; ORCHIECTOMY; PROSTATIC NEOPLASMS; STROKE;

AGED; ANDROGEN ANTAGONISTS; COHORT STUDIES; DENMARK; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MYOCARDIAL INFARCTION; ORCHIECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; STROKE;

EID: 84894442854     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.02.002     Document Type: Article

References (32)

1. N. Mottet, J. Bellmunt, and M. Bolla et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 59 2011 572 583
2. V.B. Shahinian, Y.F. Kuo, J.L. Freeman, E. Orihuela, and J.S. Goodwin Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma Cancer 103 2005 1615 1624
3. M. Braga-Basaria, A.S. Dobs, and D.C. Muller et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy J Clin Oncol 24 2006 3979 3983
4. S. Basaria, D.C. Muller, M.A. Carducci, J. Egan, and A.S. Dobs Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy Cancer 106 2006 581 588
5. J.C. Smith, S. Bennett, and L.M. Evans et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer J Clin Endocrinol Metab 86 2001 4261 4267
6. M.R. Smith, H. Lee, and D.M. Nathan Insulin sensitivity during combined androgen blockade for prostate cancer J Clin Endocrinol Metab 91 2006 1305 1308
7. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456
8. N.L. Keating, A.J. O'Malley, S.J. Freedland, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer J Natl Cancer Inst 102 2010 39 46
9. M. Van Hemelrijck, H. Garmo, and L. Holmberg et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden J Clin Oncol 28 2010 3448 3456
10. L. Azoulay, H. Yin, S. Benayoun, C. Renoux, J.-F. Boivin, and S. Suissa Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer Eur Urol 60 2011 1244 1250
11. A.V. D'Amico, J.W. Denham, and J. Crook et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions J Clin Oncol 25 2007 2420 2425
12. C.S. Saigal, J.L. Gore, and T.L. Krupski et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer Cancer 110 2007 1493 1500
13. E. Martin-Merino, S. Johansson, T. Morris, and L.A. Garcia Rodriguez Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care Drug Saf 34 2011 1061 1077
14. S.M. Alibhai, M. Duong-Hua, and R. Sutradhar et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes J Clin Oncol 27 2009 3452 3458
15. U.E. Studer, P. Whelan, and W. Albrecht et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORCT) trial 30891 J Clin Oncol 24 2006 1868 1876
16. M. Roach, K. Bae, and J. Speight et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610 J Clin Oncol 26 2008 585 591
17. J.A. Efstathiou, K. Bae, and W.U. Shipley et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31 J Clin Oncol 27 2009 92 99
18. A. Nanda, M.-H. Chen, and B.J. Moran et al. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease Eur Urol 65 2014 177 185
19. M. Schmidt, J.B. Jacobsen, T.L. Lash, H.E. Botker, and H.T. Sorensen 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study BMJ 344 2012 e356
20. A. Ingeman, G. Andersen, H.H. Hundborg, M.L. Svendsen, and S.P. Johnsen In-hospital medical complications, length of stay, and mortality among stroke unit patients Stroke 42 2011 3214 3218
21. L. Frank Epidemiology. When an entire country is a cohort Science 287 2000 2398 2399
22. H.H. Storm, E.V. Michelsen, I.H. Clemmensen, and J. Pihl The Danish Cancer Registry-history, content, quality and use Dan Med Bull 44 1997 535 539
23. International statistical classification of diseases and related health broblems. 10th Revision. World Health Organization. http://apps.who.int/ classifications/icd10/browse/2010/en.
24. E. Lynge, J.L. Sandegaard, and M. Rebolj The Danish National Patient Register Scand J Public Health 39 2011 30 33
25. Danish National Board of Health. Classification of diseases, 8th Rev, ed. 2. Copenhagen: Schultz Grafics; 1986.
26. H.T. Sorensen, A.M. Thulstrup, and L. Mellemkjar et al. Long-term survival and cause-specific mortality in patients with cirrhosis of the liver: a nationwide cohort study in Denmark J Clin Epidemiol 56 2003 88 93
27. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383
28. P. Henrikson, and O. Edhag Orchiectomy versus oestrogen for prostatic cancer: cardiovascular effects B Med J 293 1986 413 415
29. K. Fall, F. Fang, and L.A. Mucci et al. Immediate risk for cardiovascular events and suicide following a prostate cancer diagnosis: prospective cohort study PLoS Med 6 2009 e1000197
30. F. Dong, D.C. Skinner, and T.J. Wu et al. The heart: a novel gonadotrophin-releasing hormone target J Neuroendocrinol 23 2011 456 463
31. G.N. Levine, A.V. D'Amico, and P. Berger et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology CA Cancer J Clin 60 2010 194 201
32. C. Jespersen, M. Borre, and M. Nørgaard Validity of the recorded codes of gonadotropin-releasing hormone agonist treatment and orchiectomies in the Danish National Patient Registry J Clin Epidemiol 2012 2012 145 149